Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Detalimogene Voraplasmid
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Deep Track Capital
Deal Size : $60.0 million
Deal Type : Private Placement
enGene Announces $60 Million Private Placement Financing
Details : The proceeds from the financing will used to fund the continued development of EG-70 (detalimogene voraplasmid), which is being evaluated for the BCG-unresponsive non-muscle invasive bladder cancer.
Product Name : EG-70
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
October 25, 2024
Lead Product(s) : Detalimogene Voraplasmid
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Deep Track Capital
Deal Size : $60.0 million
Deal Type : Private Placement
Lead Product(s) : Detalimogene Voraplasmid
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Detalimogene Shows 71% Complete Response Rate in LEGEND Pivotal Cohort Analysis
Details : EG-70 (detalimogene voraplasmid) is a IL-12 inhibitor gene therapy, which is being evaluated for the treatment of BCG-unresponsive non-muscle invasive bladder cancer.
Product Name : EG-70
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
September 26, 2024
Lead Product(s) : Detalimogene Voraplasmid
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Detalimogene Voraplasmid
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Adage Capital Partners
Deal Size : $200.0 million
Deal Type : Private Placement
enGene Announces Oversubscribed $200 Million Private Placement Financing
Details : The net proceeds will be used for the clinical development of EG-70 (detalimogene voraplasmid) for non-muscle-invasive bladder cancer that is unresponsive to Bacillus Calmette-Guerin treatment.
Product Name : EG-70
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
February 14, 2024
Lead Product(s) : Detalimogene Voraplasmid
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Adage Capital Partners
Deal Size : $200.0 million
Deal Type : Private Placement
Lead Product(s) : Detalimogene Voraplasmid
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Hercules Capital
Deal Size : Undisclosed
Deal Type : Financing
enGene Announces Expanded $50 Million Debt Facility with Hercules Capital
Details : The financing will be used for the advancement of EG-70 (detalimogene voraplasmid) as an entirely new genetic medicine approach to treat BCG-unresponsive non-muscle invasive bladder cancer.
Product Name : EG-70
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
December 22, 2023
Lead Product(s) : Detalimogene Voraplasmid
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Hercules Capital
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : Detalimogene Voraplasmid
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Forbion
Deal Size : $115.0 million
Deal Type : Financing
Details : The net proceeds are expected to be used to fund the clinical development of intravesical EG-70 (detalimogene voraplasmid), a monotherapy for Bacillus Calmette-Guérin (BCG)-unresponsive NMIBC with CIS.
Product Name : EG-70
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
May 17, 2023
Lead Product(s) : Detalimogene Voraplasmid
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Forbion
Deal Size : $115.0 million
Deal Type : Financing
Lead Product(s) : Detalimogene Voraplasmid
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : EG-70 is a novel non-viral gene therapy encoding two RIG-I agonists to stimulate the innate immune system, and IL-12 to stimulate the adaptive immune system. It is being investigated for NMIBC in patients with carcinoma in situ that are BCG-unresponsive.
Product Name : EG-70
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
February 14, 2023
Lead Product(s) : Detalimogene Voraplasmid
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Detalimogene Voraplasmid
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
enGene Gets FDA Clearance of IND Application for EG-70
Details : The study design consists of an open label dose escalation Phase 1 study to evaluate the safety and tolerability of EG-70 and to determine the recommended Phase 2 dose, followed by a Phase 2 portion to evaluate efficacy and safety.
Product Name : EG-70
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
February 11, 2020
Lead Product(s) : Detalimogene Voraplasmid
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable